Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction: Insights from the EXAMINATION trial

Josep Gomez Lara, S Brugaletta, JA Gomez-Hospital, JL Ferreiro, G Roura, R Romaguera, V Martin-Yuste, M Masotti, A Iniguez, A Serra, R Hernandez-Antolin, V Mainar, M (Marco) Valgimigli, M Tespili, P den Heijer, A Bethencourt, N Vazquez, PWJC (Patrick) Serruys, M Sabate, A Cequier

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)


Background ST-elevation myocardial infarctions (STEMI) caused by proximal left-anterior descending (LAD) lesions have more myocardium at risk and worse outcomes than those located in other segments. The aim is to compare outcomes of patients with STEMI and proximal-LAD lesions treated with bare-metal stents (BMS) versus everolimus-eluting stents (EES). Methods The EXAMINATION trial randomized 1498 STEMI patients to BMS versus EES. The primary end point was the patient-oriented combined of all-cause death, any-recurrent myocardial infarction (MI) and any-revascularization. The secondary end point included the device-oriented combined of cardiac death, target-vessel MI and target-lesion revascularization (TLR). Results STEMI with a proximal-LAD occlusion was observed in 290 patients (BMS = 132 and EES = 158). Both groups were similar except for diabetes (12.9% vs 24.1%; P = .016). At 1 year, the primary end point was observed in 18.9% and 9.5% of patients treated with BMS and EES, respectively (P = .023). The secondary end point was observed in 11.4% and 5.1%, respectively (P = .053). There were no differences in cardiac death (4.5% vs 3.8%; P = .750) and MI (1.5% vs 0%; P = .121). BMS had higher rate Patients with proximal-LAD STEMI had higher mortality than patients with non proximal-LAD STEMI (5.5% vs 2.9%; P = .027). Proximal-LAD lesions treated with BMS tended to increase the risk of the primary end point compared with other segments (18.9% vs 13.0%; P = .079). However, EES implanted in proximal-LAD had similar outcomes compared with other locations (9.5% vs 12.0%; P = .430). Adjusting for confounders, the interaction between BMS and proximal-LAD location was associated with the primary Conclusion Patients with STEMI and proximal-LAD lesions treated with EES have better outcomes compared with BMS at 1 year. Although further investigations are required, it seems reasonable to consider EES for proximal-LAD STEMI-lesions.
Original languageUndefined/Unknown
Pages (from-to)119-+
JournalAmerican Heart Journal
Issue number1
Publication statusPublished - 2013

Cite this